arrow
Y

Yunfang Yu

sun yat-sen university
H指数:24
被引数:2,709

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Genetically Engineered Probiotic Nanoplatform for Ultrasound-Enhanced Colorectal Cancer Therapy via Targeted Delivery, Immune Modulation, and Anti-Angiogenesis

基因工程益生菌纳米平台通过靶向递送、免疫调节和抗血管生成实现超声增强的结直肠癌治疗

MedComm
IF10.7
2026-07-280
OAAI
Single-Cell and Spatial Transcriptomics Uncover Immune Dynamics and Cellular Heterogeneity in Benign Prostatic Hyperplasia and Prostate Cancer Transition

单细胞和空间转录组学揭示良性前列腺增生和前列腺癌转化中的免疫动态和细胞异质性

MedComm
IF10.7
2026-05-230
OAAI
Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial

氟维司群与卡培他滨作为激素受体阳性HER2-negative转移性乳腺癌一线化疗后的维持治疗 (FAMILY): 一项多中心、开放标签、随机、3期临床试验

2026-05-220
OAAI
Artificial Intelligence-Based Multimodal Prediction of Postoperative Adjuvant Immunotherapy Benefit in Urothelial Carcinoma: Results From the Phase III, Multicenter, Randomized, IMvigor010 Trial

基于人工智能的多模态预测在尿路上皮癌术后辅助免疫治疗获益中的应用:IMvigor010 III期、多中心、随机临床试验结果

MedComm
IF10.7
2025-08-250
OAAI
Tumor microenvironment RNA test to predict immunotherapy outcomes in advanced gastric cancer: The TIMES001 trial
MED
IF11.8
2024-11-010
PRE
Four-year outcomes from GEMSTONE-302 study: First-line sugemalimab plus platinum-based chemotherapy in metastatic non-small cell lung cancer (NSCLC)

GEMSTONE-302研究四年随访结果:转移性非小细胞肺癌(NSCLC)一线治疗中使用苏格莫利单抗联合铂类为基础的化疗

2024-09-011
PRE
Artificial intelligence enables precision diagnosis of cervical cytology grades and cervical cancer

人工智能可实现宫颈细胞学分级和宫颈癌的精确诊断

2024-05-222
OAAI